This article has no abstract.

Endometrial cancer affects the uterus and is becoming increasingly common deadly. Although surgery adjuvant pelvic radiotherapy can often cure disease when it contained in uterus, patients with metastatic or recurrent have limited response rates to chemotherapy, targeted agents, hormonal therapy. To address this unmet clinical need, innovative treatment strategies are needed, a growing focus on...

dendritic cells (dcs) are antigen presenting cells with unique capability to take up and process antigens in the peripheral blood and tissues. they subsequently migrate to draining lymph nodes where they present these antigens and stimulate naive t lympho-cytes. during their life cycle, dcs go through two maturation stages and are referred to as immature and mature cells, respectively. while im...

the b-cell cd20 antigen is one of the most reliable surface targets in immunotherapy of b lymphoma. in this project, we studied the production and characterization of a new monoclonal antibody against chimeric human cd20 extra loops (hcd20 exl). the results showed that clone c12h, igg2/k isotype reacted with the antigen in elisa and immunoblot. the kd value was  found to be 2×10-9m and flow cyt...

introduction: epidermal growth factor receptor (egfr) has been shown to play a critical role in tumor cell growth and its overexpression has been observed in many epithelial tumors. in the field of cancer vaccine research, displaying the peptide mimotope on the surface of phage particles has shown promising results. methods: in this study using m13-pviii phage display system, two constructs wer...

Epidermal Growth Factor Receptor (EGFR or HER1) is considered a tumor associated antigen. HER1 is overexpressed in many human epithelial tumors and involved in crucial cellular functions for tumor development. For this reason HER1 is considered a good target for cancer immunotherapy and some passive agents are being evaluated in clinical trials. However, HER1-based active immunotherapy has not ...

Immunotherapy of tuberculosis (TB) has long been considered to be a potential adjunct to chemotherapy, by targeting ‘persister’ organisms which are generated during chemotherapy. In this chapter, we briefly review the current immunotherapeutic approaches in TB and then focus in more detail on a novel form of combined immunotherapy (CIT), comprising an IgA monoclonal antibody (mAb) against the ...

Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses. We have recently reported the immunogenicity of HER2 subdomains following DNA immunization and HER2 protein boosting. In the present study, we evaluated the immunogenicity of different HER2 ex...